Trials / Recruiting
RecruitingNCT06687070
APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of APG-2449 Monotherapy or in Combination With Anticancer Agents in Patients With Platinum-resistant Recurrent Ovarian Cancer or Advanced Solid Tumors
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- Ascentage Pharma Group Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
An open, multicenter, dose-exploring Phase I trial include Part A and Part B to evaluate the safety, tolerability and efficacy of APG-2449.
Detailed description
Part A: To evaluate the safety of APG-2449 monotherapy in patients with advanced solid tumors. Part B: To evaluate the safety, tolerability, and efficacy of APG-2449 combined with PLD in the treatment of ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | APG -2449 | Orally once a day(QD), every 28 days as a cycle. |
| DRUG | PLD | Injected on the first day of each cycle, every 28 days as a cycle. |
Timeline
- Start date
- 2024-12-17
- Primary completion
- 2026-05-01
- Completion
- 2027-05-01
- First posted
- 2024-11-13
- Last updated
- 2025-02-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06687070. Inclusion in this directory is not an endorsement.